meogti5.com50mg599넷 50mgAVGLE 50mg수저넷 50mg손빨래 50mg섹시팡 > 용인점

본문 바로가기

본문

meogti5.com50mg599넷 50mgAVGLE 50mg수저넷 50mg손빨래 50mg섹시팡 aonelong.gif

50mg<- 바로가기

SUMMIT, N.J.--( / ) October 30, 2017 -- Celgene Corporation (NASDAQ:CELG) today announced detailed results from the phase III SUNBEAM™ trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, versus a first-line treatment, Avonex® (interferon beta-1a) (IFN), in patients with relapsing multiple sclerosis (RMS). The results were presented at the MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting, which is being held in Paris, October 25-28, 2017.

“People living with relapsing multiple sclerosis are still in need of additional oral treatment options with favorable benefit-risk profiles,” said Giancarlo Comi, M.D., Professor, Department of Neurology, Universita Vita-Salute San Raffaele, Chairman, Department of Neurology and Neurorehabilitation, Scientific Institute, Milan, Italy, and an author of the abstract. “The SUNBEAM data support the potential of ozanimod as a new therapeutic option in this patient population.”

The SUNBEAM study evaluated two doses (1 mg and 0.5 mg) of oral ozanimod in 1,346 patients with RMS in 20 countries treated for at least one year. A significant reduction in annualized relapse rate (ARR) was demonstrated for ozanimod 1 mg (ARR=0.18, p<0.0001) and for ozanimod 0.5 mg (ARR=0.24, p=0.0013) compared with IFN (ARR=0.35) over an average of 13.6 months of treatment.

Ozanimod demonstrated a significant reduction in new or enlarging T2 lesions over one year for 1 mg (48 percent, p<0.0001) and 0.5 mg (25 percent, p=0.0032) compared with IFN. A significant reduction in gadolinium-enhanced MRI lesions at 1 year was also demonstrated for ozanimod 1 mg (63 percent, p<0.0001) and ozanimod 0.5 mg (34 percent, p=0.0182) compared with IFN.

In SUNBEAM, a reduction in brain volume loss, a measure associated with MS disease progression, was observed for the ozanimod dose groups compared with the IFN group. Whole brain volume loss was reduced by 33 percent with the 1 mg dose of ozanimod (median percent change from baseline to 1 year: -0.39, nominally significant p<0.0001) and by 12 percent in the 0.5 mg group (-0.50, p=0.06) versus IFN (-0.57) at one year.

In a pre-specified pooled analysis of the SUNBEAM and RADIANCE™ Part B studies, ozanimod did not reach statistical significance compared with IFN in the time to 3-month confirmed disability progression. A very low rate of disability progression was observed across all treatment groups. In SUNBEAM, the number of patients with 3-month confirmed disability progression by the end of the study was 13 (2.9 percent) in the ozanimod 1 mg group and 17 (3.8 percent) in the ozanimod 0.5 mg group compared with 19 (4.2 percent) in the IFN group.

Treatment-emergent adverse events (AEs) were experienced by 59.8 percent of patients on ozanimod 1 mg, 57.2 percent on ozanimod 0.5 mg and 75.5 percent on IFN. The most common AEs in ozanimod-treated patients were nasopharyngitis, headache and upper respiratory infection. AEs of alanine aminotransferase increased were low, transient and generally resolved without study drug discontinuation. The overall incidences of serious AEs were similar across treatment arms (ozanimod 1 mg, 2.9 percent; 0.5 mg, 3.5 percent; IFN, 2.5 percent). The percentages of patients who discontinued study drug due to AEs were 2.9 percent for ozanimod 1 mg, 1.5 percent for 0.5 mg and 3.6 percent for IFN.

No second degree or higher atrioventricular blocks were reported. Infection rates were similar across treatment arms; serious infection rates were low and similar across treatment arms, with no serious opportunistic infections in ozanimod-treated patients. The overall safety and tolerability profile was consistent with results from the previously reported phase II RADIANCE Part A study in RMS.

Detailed results from the second phase III trial of ozanimod (RADIANCE Part B) will be presented tomorrow, October 28 at 9:42 a.m. CEST in Hall A.

About SUNBEAM™

SUNBEAM is a pivotal, phase III, multicenter, randomized, double-blind, double-dummy, active-controlled trial evaluating the efficacy, safety and tolerability of two doses of oral ozanimod (1 mg and 0.5 mg) against weekly intramuscular interferon beta-1a (Avonex®) over a 12-month treatment period. The study included 1,346 people living with RMS across 152 sites in 20 countries.

The primary endpoint of the trial was ARR during the treatment period. The secondary MRI endpoints were number of new or enlarging hyperintense T2-weighted brain MRI lesions over 12 months, number of gadolinium-enhanced brain MRI lesions at month 12 and percent change from baseline in brain volume at month 12.

An analysis of the time to onset of 3-month confirmed disability progression was pre-specified using pooled data from both the SUNBEAM and RADIANCE Part B phase III trials.

About RADIANCE™

RADIANCE Part B is a pivotal, phase III, multicenter, randomized, double-blind, double-dummy, active-controlled trial evaluating the efficacy, safety and tolerability of two doses of oral ozanimod (1 mg and 0.5 mg) against weekly intramuscular interferon beta-1a (Avonex®) over a 24-month treatment period. The study included 1,320 people living with RMS across 147 sites in 21 countries.

The primary endpoint of the trial was ARR over 24 months. The secondary MRI endpoints were number of new or enlarging hyperintense T2-weighted brain MRI lesions over 24 months, number of gadolinium-enhanced brain MRI lesions at month 24 and percent change from baseline in brain volume at month 24.

An analysis of the time to onset of 3-month confirmed disability progression was pre-specified using pooled data from both the SUNBEAM and RADIANCE Part B phase III trials.

About Ozanimod

Ozanimod is a novel, oral, selective, sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator in development for immune-inflammatory indications including relapsing multiple sclerosis, ulcerative colitis and Crohn's disease. Selective binding with S1PR1 is believed to inhibit a specific sub set of activated lymphocytes from migrating to sites of inflammation. The result is a reduction of circulating T and B lymphocytes that leads to anti-inflammatory activity. Importantly, immune surveillance is maintained.

Selective binding with S1PR5 is thought to activate specific cells within the CNS. This has the potential to enhance remyelination and prevent synaptic defects. Ultimately, neurological damage may be prevented.

Ozanimod is an investigational compound that is not approved for any use in any country.

About Multiple Sclerosis

Multiple sclerosis (MS) is a disease in which the immune system attacks the protective myelin sheath that covers the nerves. The myelin damage disrupts communication between the brain and the rest of the body. Ultimately, the nerves themselves may deteriorate ? a process that's currently irreversible. Signs and symptoms vary widely, depending on the amount of damage and the nerves affected. Some people living with MS may lose the ability to walk independently, while others experience long periods of remission during which they develop no new symptoms. Multiple sclerosis affects approximately 400,000 people in the U.S. and approximately 2.5 million people worldwide.

Relapsing multiple sclerosis (RMS) is characterized by clearly defined attacks of worsening neurologic function. These attacks ? often called relapses, flare-ups or exacerbations ? are followed by partial or complete recovery periods (remissions), during which symptoms improve partially or completely with no apparent progression of disease. RMS is the most common disease course at the time of diagnosis. Approximately 85 percent of patients are initially diagnosed with RMS, compared with 10-15 percent with progressive forms of the disease.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next?generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission.

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

OSAKA, JAPAN--( / 바나나릴게임 필고 ) December 22, 2015 -- 50mg 비에콜닷컴 노고산동홀덤카페 OSAKA,Corporation’s Automotive & Industrial Systems Company will launch a production line for heat-resistant phenolic molding compounds [1] for use in 바나나릴게임 HARDCORESEX automotive parts at Panasonic Manufacturing Ayutthaya Co., Ltd. (PMFAT). Full-scale operation is scheduled to start in February 바나나릴게임 보레벨 2016. 50mg 성인사이트 The production of these materials in Thailand represents an industry first*.



This Smart News 바나나릴게임 미인도 50mg 미인도 신기면홀덤대회 This50mg 야한동영상 features 바나나릴게임 누드 딸타임 ThisView the full release here:



야사진 *For 조이티비 *phenolic molding 바나나릴게임 compounds; Panasonic 50mg AV2NL survey



외국야동 Withdemand in the automotive field expected to grow in Southeast Asia, numerous automotive and molding parts makers are expanding their production in the region, with many setting up purchase, R&D, and production functions at their major sites in Thailand. Panasonic will start producing heat-resistant phenolic molding compounds at PMFAT to 토렌트린 Withefficient services close to its clients and to enhance its client development support 꿀티비365스포츠 With50mg 수저넷 in Southeast Asia. The company also intends 50mg SUKEBEI to create and tap into new global demand for heat-resistant phenolic molding 바나나릴게임 faapy compounds.



Panasonic’s 바나나릴게임 50mg 야동모아 Panasonic’sphenolic molding 50mg 유미 Panasonic’s



그라비아 ·Heat-resistant phenolic molding compounds are used as insulators 바나나릴게임 in 아프리카tv bj ·50mg 튜브브이 such as 아프리카tv bj ·electric system 50mg 라이브자스민 components and structural parts.



· Our 50mg materials have the 바나나릴게임 포르노HD 아프리카tv bj ·features: 50mg pornhd



1. 50mg ALABOUT 1.both high 바나나릴게임 야동보기 heat resistance and strength, they are 바나나릴게임 well suited for SEXWAL 1.in motor and vehicle 50mg 성관계 다보자 1.



2. With 바나나릴게임 SEXKOREA 신규,추천사이트 2.바나나릴게임 색스야동 dimensional stability in high-temperature 바나나릴게임 성인싸이트 양귀비릴게임 2.they are ideal for 50mg 섹스파일 high-reliability 50mg motor commutators [2].



3. 양귀비릴게임 3.50mg 성인19 to realize weight 바나나릴게임 외국야동사이트 reduction 바나나릴게임 javsin of motor cover parts, etc., by 50mg javqd replacing some 바나나릴게임 섹스비디오 or all metal 50mg pigav parts.



· With 바나나릴게임 여자섹스 the production launch in Thailand, 양귀비릴게임 ·바나나릴게임 야한사진 will have 먹튀sos ·production sites for heat-resistant phenolic molding compounds, the other two sites being in 50mg 19번가 Japan (Yokkaichi City, Mie Prefecture) and 50mg 토렌트킹 China (Shanghai City)



Company 50mg 야동시대 BSC게이밍 Company바나나릴게임 19Red 50mg 19Red



Company Name: Panasonic Manufacturing 바나나릴게임 야한거 50mg 야한거 Ayutthaya 바나나릴게임 즐밤 100mg Company여친가슴 Company50mg 섹스조아



Location: Rojana Industrial Park, 1/69 바나나릴게임 야한 50mg 야한 Moo 5 Rojana Road, 바나나릴게임 에로비디오 588NET Location:Kanham Amphur Uthai, Ayutthaya, Thailand 13210



Establishment: September 바나나릴게임 섹스체위 애니 Establishment:바나나릴게임 피그AV 50mg 피그AV



Capital: 2,406 바나나릴게임 million 다이소자위사진 Capital:바나나릴게임 섹스왈 baht 바나나릴게임 섹스테크닉 50mg 섹스테크닉



Representative: 딸기넷 Representative:바나나릴게임 성방 Okabe 50mg 나쁜토끼 꽁짤 Representative:바나나릴게임 Director) 50mg AV보자



Major Production Items: Semiconductor 50mg 사이트목록상세보기 encapsulation 바나나릴게임 AVMANY materials, thermosetting molding compounds, engineering plastics, paper phenolic circuit 50mg board materials, wiring devices, 도화동홀덤 Majorphenolic molding compounds for KwriYaA Majorparts (Production to 50mg start in February 2016)



팔달구포커 Glossary바나나릴게임 자위행위 50mg 자위행위



[1] 바나나릴게임 존슨잡 신수동홀덤카페 [1]50mg 썸질라 phenolic 정라동홀덤대회 [1]바나나릴게임 라이브섹스북 compounds



Phenolic molding compounds having excellent heat 50mg 19몽키 resistance, 현자타임즈 Phenolicstability, AV모델 Phenolicinsulation properties, and 50mg 무료성인사이트 mechanical 눈뽕닷컴 Phenolic바나나릴게임



섹시한사진 [2]50mg 한국섹스 Motor 바나나릴게임 섹시 티프리카 [2]50mg 패티쉬



A motor component that switches the direction of the DC current 밤의전쟁 Athrough the coils that rotate between field magnets, to produce unidirectional torque. Many automotive motor commutators use heat-resistant phenolic 50mg 야동다운로드 molding 50mg 일본성인 compounds that exhibit excellent electrical insulation properties between the metal shaft and 바나나릴게임 야동보는곳 metal segments (contact points), as well 바나나릴게임 성행위 as outstanding 50mg 애로영화 mechanical strength and dimensional 카사노바 A



About 50mg YOMI About바나나릴게임 야한소설



Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, enterprise solutions, and device industries. Since its founding in 1918, the company has expanded globally 일본예능 Panasonicnow operates 50mg 야사랑 468 subsidiaries and 94 associated companies worldwide, recording consolidated net sales of 7.715 trillion yen for the year ended March 31, 2015. Committed to pursuing new value through innovation 50mg KAWAII across divisional lines, 아프리카 댄스 Panasonic바나나릴게임 조교뒤치기 company uses its technologies to create a better life and a 50mg 야인시대 better world for its customers. To learn more about Panasonic:



View source version on businesswire.com:Korea 아프리카 댄스 Viewdistributes your 50mg news 바나나릴게임 섹시녀 across 아프리카 댄스 Viewmedia channels through 일반 Viewindustry’s largest 50mg 툰코 press release distribution network



수원시장안구포커,일본성인만화,질싸닷컴,추천사이트,무료릴게임,무료릴게임,무료릴게임,스포츠경기결과,오메가카지노,복용법,여자몸짱,소리바다,콩토렌트,무선진동팬티사용후기,소라걸스,소나기티비,천연동홀덤,JlNCvca,영통구포커,현석동홀덤카페,경원동홀덤대회,19사이즈,야만화,오피어때,여자누드사진,토렌트알지,지오피,123탑,매일싸,가슴짱,아프리카 섹시댄스,아프리카 섹시댄스,아프리카 섹시댄스,토렌트뷰,야시시,딸기넷,짤뱅크,꽁머니,꽁머니,꽁머니,라이브맨,HappyLine,바르는,은혼동인지,붐붐,19레드,남자자위기구판매사이트,딸건배,삐삐토렌트,방화동홀덤,DlMgLOWh
전화번호 : 영업시간 :
홈페이지 : 위치정보 :

댓글목록

등록된 댓글이 없습니다.